Wheat-Derived Peptides Lower Blood Pressure in Hypertensive Rats Through Multiple Mechanisms

Wheat oligopeptides were produced by enzymatic hydrolysis of wheat protein. ACE inhibitory activity was measured in vitro. In vivo experiments used spontaneously hypertensive rats (SHRs) — a well-established animal model for essential hypertension. Blood pressure was measured over the treatment period. Kidney and heart tissues were examined for oxidative stress and inflammation markers. Signaling pathway activation was assessed through molecular analysis of relevant proteins.

Hypertension affects over a billion people worldwide and is a leading cause of heart disease, stroke, and kidney failure. While synthetic ACE inhibitors are effective, they carry side effects. Food-derived peptides that lower blood pressure through multiple complementary mechanisms — ACE inhibition, anti-inflammation, and antioxidant protection — could offer a gentler, more holistic approach through functional foods.

Food-derived antihypertensive peptides are a rapidly growing research area as consumers and healthcare systems seek natural approaches to managing blood pressure. While most prior work has focused on milk- and fish-derived peptides, this study highlights wheat as a promising and widely available source. The multi-mechanistic action — beyond simple ACE inhibition — sets wheat oligopeptides apart from many food-derived alternatives.

This is an animal study using a specific rat model of hypertension; results may not directly translate to humans. The exact peptide sequences responsible for the antihypertensive effects were not individually identified. Dosing, bioavailability, and long-term safety in humans have not been evaluated. No comparison with standard antihypertensive drugs was reported.